

Neuroprotective role of Asiatic acid in aluminium chloride induced rat model of Alzheimer's disease

Mashoque Ahmad Rather¹, Arokiasamy Justin Thenmozhi¹, Thamilarasan Manivasagam¹, Mathiyazahan Dhivya Bharathi¹, Musthafa Mohamed Essa^{2,3,4}, Gilles J. Guillemin⁵

¹Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Tamil Nadu 608002, India, ²Department of Food Science and Nutrition, CAMS, Sultan Qaboos University, Muscat, Oman, ³Ageing and Dementia Research Group, Sultan Qaboos University, Muscat, Oman, ⁴Food and Brain Research Foundation, Chennai, Tamil Nadu 600094, India, ⁵Neuroinflammation group, Faculty of Medicine and Health Sciences, Macquarie University, NSW, Australia

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Methods
 - 3.1. Animals
 - 3.2. Chemicals
 - 3.3. Experimental design
 - 3.3.1. Preparation of Asiatic acid
 - 3.3.2. Phase I experiment
 - 3.3.3. Phase II experiment
 - 3.3.4. Morris water maze test
 - 3.3.5. Passive avoidance task
 - 3.3.6. Determination of Al concentration
 - 3.3.7. Activity of AChE
 - 3.3.8. Western blot analysis
 - 3.3.9. Data analysis
4. Results
 - 4.1. AA dose dependently attenuated the $AlCl_3$ induced Al load and AChE activities
 - 4.2. AA attenuated $AlCl_3$ induced learning and memory deficits
 - 4.3. AA protected $AlCl_3$ induced A β burden
 - 4.4. AA ameliorated $AlCl_3$ influenced Inflammation
5. Discussions
6. Acknowledgments
7. References

1. ABSTRACT

Alzheimer's disease (AD) is the most common form of dementia, characterized by memory loss, cognitive impairment and personality disorders accompanied by diffuse structural abnormalities in the brain of elderly people. The current investigation explored the neuroprotective potential of asiatic acid (AA), a natural triterpene of *Centella asiatica* on aluminium chloride ($AlCl_3$) induced rat model of AD. Oral administration of $AlCl_3$ (100 mg/kg b.w.) for 42 days significantly elevated the levels of Al, activity of acetyl cholinesterase and expressions of amyloid precursor protein, amyloid beta₁₋₄₂, beta and gamma

secretases, glial fibrillary acidic protein, ionized calcium binding adaptor molecule 1, interleukins -1 β , 6, 4, 2, tumor necrosis factor alpha, inducible nitric oxide synthase, nuclear factor- κ beta and cyclooxygenase-2 in the hippocampus and cortex compared to the control group. Our observations suggested that AA treatment mitigated $AlCl_3$ induced AD associated pathologies, which might be due to its multiple pharmacological actions. Further studies are necessary in order to explore the link between $AlCl_3$ -mediated oxidative stress and associated apoptosis to establish its neuroprotective role in AD.

2. INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disease, associated with the loss of memory, language and other cognitive impairments in aged population. Accumulation of extracellular amyloid β peptide ($A\beta$) containing plaques through amyloidogenic pathway and intraneuronal fibrillary tangles in the brain are two critical features in the neuropathogenesis of AD, consequently destroys the neurons slowly. The cause of AD is multifactorial and apparently entails numerous factors including head trauma, genetics, oxidative stress, inflammation, proteosomal dysfunction and environmental features such as aluminium (Al) toxicity. Al is an abundantly existing neurotoxin, extremely exposed to humans and shown to accumulate in AD vulnerable brain regions such as cortex and hippocampus (1-3). Furthermore, Al diverts amyloid precursor protein (APP) metabolism from its non-amyloidogenic pathway to amyloidogenic pathway, thereby favours the formation of β -amyloid oligomers, fibrils and plaques (4).

Al inhibits long-term potentiation, induces inflammatory responses, affects the slow and fast axonal transports and causes synaptic structural abnormalities, resulting in profound memory loss (5). Becaria *et al.* (6) and Ghribi *et al.* (7) found that Al exposure activated nuclear factor kappa B (NF- κ B), which is the regulator of inflammatory markers such as cyclooxygenase-2 (COX-2), IkB, TNF- α , cyclin D1, intercellular adhesion molecule-1 (ICAM-1), inducible nitric oxide synthase (iNOS) and interleukins-6 and -8 (IL-6, IL-8) by inducing the degradation of inhibitor kappa B (IkB) (8).

In Ayurvedha, Mandukaparni (*Centella asiatica*) is described as "Medhya Rasayana" or brain tonic, which possesses various effects on CNS such as nerve stimulatory tonic, rejuvenator of memory, learning, sedative, tranquilizer and intelligence promoting properties. *Centella asiatica* (CA) has been shown to enhance the capability of rats in performing several memory tasks, including the Morris water maze and passive avoidance test (9). It is demonstrated that CA protected $A\beta$ toxicity in *in vitro* and *in vivo* conditions (10, 11). The neuroprotective effect of CA was explored against aluminium-induced mitochondrial dysfunction, oxidative stress, apoptosis and cognitive impairment in experimental AD rats (12). Based on the numerous studies, the medicinal values of this plant are mainly attributed due to the presence of several triterpenes, namely asiatic acid, madecassic acid, asiaticoside and madecassoside (13). Krishnamurthy *et al.* (14) reported that asiatic acid (AA), a tri-terpene of CA could transverse the blood-brain barrier and mitigated mitochondrial injury in a mouse model of focal cerebral ischemia. Many previous studies revealed that this compound was

a potent protective agent for brain against various neurotoxins (15-19).

Though the Al exposure is involved in the development of clinical and pathological features of AD in rats (2, 3, 20, 21), the underlying mechanism by which AA exerts its neuroprotective action in animal model is still unravelling. Based on this background, the present study was carried out to explore the neuroprotective effect of AA against $AlCl_3$ induced alterations on the level of aluminium, activity of AChE and expressions of APP, $A\beta_{1-42}$, β - and γ -secretases and inflammatory indices in hippocampus and cortex of rats.

3. MATERIALS AND METHODS

3.1. Animals

Male Albino Wistar rats (200–225 g) were procured from Central Animal House, Rajah Muthiah Medical College & Hospital, Annamalai University and were maintained at standard conditions with food and water *ad libitum*. The experimental protocols were approved by the Institutional Animal Ethics Committee (Reg. No. 160/1999/CPCSEA, Proposal No. 1006) and met with the guidelines of Indian National Science Academy, New Delhi, 2000.

3.2. Chemicals

Aluminium chloride, anti-amyloid precursor protein, anti- β -amyloid₁₋₄₂, anti- γ -, β - secretases and horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG were purchased from Sigma-Aldrich, Bangalore, India and used in this study. Anti-NF- κ B, anti-IL-2, anti-IL-4, anti-glial fibrillary acidic protein (GFAP), anti-cyclooxygenase-2 (COX-2) and anti- β -actin were procured from Cell Signaling technology, USA. Anti-inducible nitric oxide synthase (iNOS), interleukins (IL)-1 β , IL-6, IL-4, IL-2 anti-tumor necrosis factor alpha (TNF- α) and anti-ionized calcium binding adaptor molecule 1 (Iba-1) were procured from Santa Cruz Biotechnology, USA. All other chemicals used were of analytical grade.

3.3. Experimental design

3.3.1. Preparation of Asiatic acid

AA (Sigma-Aldrich, St. Louis, MO) was suspended in 0.5% carboxymethylcellulose (CMC) and administered orally for 6 weeks.

3.3.2. Phase I experiment

After a week acclimatization period, thirty six rats were divided into six groups of each containing six animals. Group I rats received CMC (0.5% in d/w).

Group II animals were treated with AlCl_3 (100mg/kg *b.w.*, oral) for 6 weeks (12). Group III rats were treated AlCl_3 as group II and subsequent oral treatment with AA (30 mg/kg *b.w.*) (14). Group IV received AlCl_3 as group II and subsequent oral treatment with AA (75 mg/kg *b.w.*) (14). Group V rats received AlCl_3 as group II and subsequent oral treatment with AA (150 mg/kg *b.w.*) (14). Group VI animals were treated with AA (150 mg/kg *b.w.*) alone.

After performing Morris water maze test, animals were sacrificed; brain tissues (cortex and hippocampus) were excised and utilized for the determination of Al and AChE. No significant changes were found in the activities of AChE between 75 mg/kg *b.w.* and 150 mg/kg *b.w.* AA co-treated rats. Hence, the dose 75 mg/kg *b.w.* AA has been used for further studies.

3.3.3. Phase II experiment

Forty eight rats were randomized and divided into four ($n = 18$) groups: control, AlCl_3 , AlCl_3 +AA (75 mg/kg *b.w.*) and AA (75 mg/kg *b.w.*) for 6 weeks. The neuroprotective efficacy of AA against AlCl_3 induced neurotoxicity was determined by performing passive avoidance test and the protein expression studies of $\text{A}\beta$ biosynthesis related and inflammatory markers.

3.3.4. Morris water maze test

The apparatus consists of a large circular swimming pool (150 x 45 cm; water filled up to the depth of 30 cm), which is divided into four equal quadrants. During the acquisition phase, each and every rat was gently placed in the different quadrants of swimming pool for each trial, facing the wall of pool and permitted 120 seconds (s) to locate the small visible platform that was placed about 1 cm above the water level. Rats were permitted to stay in the platform for 20 s. The failed animals were guided to reach the destination and allowed to remain there for next 20 s. On 19th and 20th days, the animals were permitted to go two consecutive training sessions. The mean time taken to reach the visual platform was calculated as acquisition latency. On 21st and 42nd days, after AlCl_3 administration, mean time taken to locate the hidden platform was recorded as first and second retention latencies respectively (22).

3.3.5. Passive avoidance task

The apparatus consisted of a light and dark chamber that was separated by a wall that contains a door. In the acquisition trial, rat was independently placed in the light chamber and allowed to enter into the dark chamber. Immediately electric shock (40 V, 0.5. mA for 1 s) was delivered to the feet of the animal through the metal grid. Then the rat was taken from

the apparatus and returned to the cage. After 24 h, each and every rat was placed individually again in the light chamber and the time taken by them to enter into the dark chamber was considered as step-through latency. If the rat did not enter the dark chamber within a 5-minute test period, the test was ceased and the step-through latency was noted as 300 seconds (23).

3.3.6. Determination of Al concentration

Brain tissues (cortex and hippocampus) were weighed and put into polytetrafluoroethylene (PTFE), then added 0.0.5 ml nitric acid and 0.2. ml H_2O_2 per 30 mg tissue and incubated at 120°C for 2 h. Al levels in cortex and hippocampus of control and experimental rats were measured by atomic absorption spectrophotometer (24).

3.3.7. Activity of AChE

The AChE activity was measured in the studied brain regions by spectrophotometer at 412 nm (25).

3.3.8. Western blot analysis

Brain tissues were homogenized in cold suspension lysis Hepes-KOH buffer (Hepes 25 mM; MgCl_2 5 mM; EDTA 5 mM in double distilled H_2O) and the homogenates were centrifuged (10,000 rpm/15 min/4°C). The protein content of the supernatant was assayed (26) and diluted to give equal protein concentration of 50 μg . Samples containing equal cellular protein were loaded on 10% SDS-polyacrylamide gel electrophoresis and resolved. The gel was transferred on to a polyvinylidene difluoride membrane (Millipore). To assess the expression of specific protein, the membranes were incubated with $\text{A}\beta_{1-42}$, β -, γ - secretases, GFAP, Iba-1, IL-1 β , IL-6, TNF- α , iNOS, NF- κB , COX-2 and β -actin IgG in 5% BSA in Tris-buffered saline and 0.0.5% Tween-20 (TBST) with mild shaking overnight (4°C) (27). Then the membranes were incubated for 2 h at room temperature with their corresponding HRP conjugated secondary antibodies and washed. Immunoreactive proteins were visualized by the chemiluminescence protocol (GenScript ECL kit, USA) and the densitometric analysis was performed with gel image analysis program. Data were normalised by background subtraction and β -actin was used as internal control. Bands were scanned using a scanner and quantitated by Image J, a public domain Java image processing software, which of control was set to 100.

3.3.9. Data analysis

Data were expressed as mean \pm Standard Error (SEM) of six rats for behavioural and biochemical studies and of three for protein expression studies.




Figure 1. AlCl₃ treatment enhanced the levels of Al as compared to control, whereas AA (30, 75 and 150 mg/kg b.w.) pretreatment dose dependently attenuated AlCl₃ induced Al accumulation. Data are expressed as mean \pm SD (one-way ANOVA followed by DMRT). Values not sharing same alphabet differ significantly.




Figure 2. AlCl₃ treatment enhanced the levels of activities of AChE in hippocampus and cortex of control and experimental rats as compared to control, whereas AA (30, 75 and 150 mg/kg b.w.) pretreatment dose dependently reversed these changes.

The statistical significance was calculated by one-way analysis of variance (ANOVA) using SPSS version 15.0. and the individual comparisons were obtained by Duncan's Multiple Range Test (DMRT). A value of $P < 0.05$ was considered to indicate a significant difference between groups and the values sharing a common alphabet do not differ significantly with each other.

4. RESULTS

4.1. AA dose dependently attenuated the AlCl₃ induced Al load and AChE activities

A preliminary study was conducted with three different doses of AA (30, 75 and 150 mg/kg b.w.) to determine the dose-dependent effect of AA in AlCl₃

induced AD rats. Rats treated with AlCl₃ (100 mg/kg b.w. oral) for 42 days showed a significant increase in the levels of Al (Figure 1) and activities of the AChE (Figure 2) in hippocampus and cortex. AA co-treatment dose dependently and significantly attenuated the Al levels and AChE activities in AlCl₃ induced rats. However middle (75 mg/kg b.w.) and high dose (150 mg/kg b.w.) of AA showed non-significant attenuation in Al levels and AChE activities, but more significantly than low dose (30 mg/kg). So 75 mg/kg b.w. of AA is chosen as optimum dose for further studies.

4.2. AA attenuated AlCl₃ induced learning and memory deficits

AlCl₃ treated rats took more time to reach the visible platform on 20th day in Morris water maze test




Figure 3. Effect of AA on memory and learning deficit in Morris water maze test. AICl₃ treatment significantly enhanced time taken to reach the visible and hidden platform as compared to control, whereas AA treatment diminished memory impairments. Data are expressed as mean \pm SD (one-way ANOVA followed by DMRT).




Figure 4. Effect of AA memory deficit in Passive avoidance test. AICl₃ treatment reduced the time taken to enter the dark room in the passive avoidance test as compared to control, whereas AA pretreatment reduced the memory impairments. Data are expressed as mean \pm SEM (one-way ANOVA followed by DMRT) for six rats in each group. Values not sharing the same symbol differ significantly—* $p < 0.05$ compared to the control, # $p < 0.05$ compared to the AICl₃ treated rats.

(Figure 3) and exhibited a diminished step-through latency in passive avoidance task (Fig 4) than the control group. Co-treatment of AA dose dependently and significantly reversed the AICl₃ induced memory and learning deficits as compared to AICl₃ alone treated rats. Moreover AICl₃ treatment significantly diminished the 1st and 2nd retention latencies (on days 21 and 42 respectively), whereas AA treatment significantly enhanced both the retention latencies as compared to AICl₃ alone treated rats. AA alone treated rats showed

no significant differences in behavioural patterns when compared to control animals (Figure 3, 4).

4.3. AA protected AICl₃ induced A β burden

We have performed western blot analysis to examine changes in β - amyloid metabolic markers in AICl₃ animal models with or without AA treatment. AICl₃ injection enhanced the protein expressions of APP, A β ₁₋₄₂, β and γ secretases as compared to the




Figure 5. AICl₃ diminished protein expressions of APP, A β 1-42, β and γ secretases as compared to control rats, whereas AA treatment reversed these changes. Evaluation of protein expression by using western blot. Data are expressed as mean \pm SEM (one-way ANOVA followed by DMRT) for three rats in each group. Values not sharing the same symbol differ significantly—* p < 0.05 compared to the control, # p < 0.05 compared to the AICl₃ treated rats.

control group, thereby favouring A β plaque formation. Oral administration of AA to AICl₃ treated rats showed diminished expressions of APP, A β ₁₋₄₂, β and γ secretases as compared to AICl₃ alone treated rats (Figure 5).

4.4. AA ameliorated AICl₃ influenced Inflammation

To explore the anti-inflammatory effect of AA, the protein expressions of GFAP and Iba-1 (markers of activated microglia and astrocyte) (Figure 6) were studied in the hippocampus and cortex of control and experimental rats. The expressions of these markers were found to be enhanced in the AICl₃ treated rats, whereas their expressions were reduced by AA treatment. Activation of astrocytes and microglia by

AICl₃, leads to the enhanced production of iNOS, NF- κ B, TNF- α , IL-1 β , IL-6, IL-4, IL-2 and COX-2, whereas AA treatment attenuated these indices through its anti-inflammatory properties (Figure 7,8).

5. DISCUSSION

Results of our current study indicated that the AICl₃ administration significantly increased Al levels in hippocampus and cortex of rats. As Al³⁺ and Fe³⁺ ions are similar in size, the former occupies iron-binding sites in transferrin and circulates throughout the body (28). Al first enters into the endothelial cells of blood brain barrier and then into brain cells via transferrin dependent and independent mechanisms (29). Prolonged half-life of Al (i.e. 150 days in rats) raises




Figure 6. AICl₃ injection enhanced the protein expressions of GFAP and Iba-1, markers of activated microglial and astrocytes as compared to control, whereas AA pretreatment diminished the expressions of these markers. Evaluation of protein expression by using western blot. Data are expressed as mean \pm SEM (one-way ANOVA followed by DMRT) for three rats in each group. Values not sharing the same symbol differ significantly—* $p < 0.05$ compared to the control, # $p < 0.05$ compared to the AICl₃ treated rats.

the risk of accumulation in all the regions of rat brain, particularly in hippocampus and cortex, which are the sites responsible for memory and learning (30). In our study, enhanced AI levels were found in hippocampus and cortex of AICl₃ treated rats, whereas AA offer neuroprotection in AD animals by reducing the levels of AI. Mohd Salim *et al.* (31) demonstrated that the metal chelating ability of CA, which may be attributed due the presence of active components including AA. Previous studies from our lab reported that the plant extracts such as *Emblca officinalis* (3), *Fenugreek* (23) and phytochemicals including hesperidin (2) offer neuroprotection against AI induced toxicity by diminishing their levels.

Acetylcholine(ACh)is thekeyneurotransmitter involved in the learning and memory processes and

alterations on the cholinergic activity is the main event in the neurochemical changes of AD (32). AChE is the marker enzyme for cholinergic activity that degrades and terminates the physiological action of ACh. Zatta *et al.*, (33) indicated that AI can enhance the activity of AChE by interacting with its peripheral sites and modifying the secondary structure. In the present study, the observed elevated activity of AChE in the AICl₃ treated group is ascribed due to the direct effect of AI. We found that the AA co-administration caused a significant reduction in hippocampal and cortical AChE activity. AChE has two special reactive sites: anionic and esteratic sites. Nasir *et al.*, (34) demonstrated that the inhibition of AChE activity by AA in *in vitro* condition was due to an active competition with ACh that occurs at the esteratic site on the enzyme, which is in consistent with our study.




Figure 7. AICl₃ treatment enhanced the protein expressions of IL-1 β , IL-6, IL-4, IL-2 and COX-2 as compared to control, whereas AA treatment attenuated these inflammatory markers. Evaluation of protein expression by using western blot. Data are expressed as mean \pm SEM (one-way ANOVA followed by DMRT) for three rats in each group. Values not sharing the same symbols differ significantly—* p < 0.05 compared to the control, # p < 0.05 compared to the AICl₃ treated rats.

Measurement of behavioural changes is a more sensitive indicator of neurotoxicity during AI exposure (35). West (36) demonstrated that the Morris water maze test is used to measure the memory deficits in AD like conditions by inspecting the hippocampal function. In this test, AICl₃ treated rats took more time to reach the visible platform than the control group, indicating memory deficits, whereas administration of AA significantly enhanced memory performance as compared to AICl₃ alone treated group. Initially animals are learnt to locate the hidden platform by using spatial cues and the time taken to locate the hidden platform after several days can be measured as spatial memory. We found that the administration of AICl₃ resulted in the loss of spatial as well as contextual memory, whereas AA treatment improved these cognitive impairments. In the passive avoidance task, the animal must learn to avoid or escape from an electric shock exposure

in darkness. All the nocturnal animals including rats naturally prefers dark environment, but the animal has to suppress this tendency by remembering the negative stimulus. AA markedly improved learning and memory of rodents injected with scopolamine (37) and monosodium glutamate (18), which is corroborated with our present results.

Amyloid cascade hypothesis demonstrated that the abnormal aggregation of A β in the brain is the main cause of AD that occurs due to an imbalance between A β production and A β clearance. A β ₁₋₄₂ is formed after the sequential cleavage of amyloid precursor protein (APP) by β and γ secretases in the amyloidosis pathway, whereas in the nonamyloid pathway, APP is acted by α and γ secretases, which prevents A β generation and seems to be a protective pathway (38). Previous studies from our lab indicated




Figure 8. AICl₃ elevated the protein expressions of NF-κB, TNF-α and iNOS as compared to control, whereas AA treatment attenuated these inflammatory markers. Evaluation of protein expression by using western blot. Data are expressed as mean ± SEM (one-way ANOVA followed by DMRT) for three rats in each group. Values not sharing the same symbols differ significantly—**p* < 0.05 compared to the control, #*p* < 0.05 compared to the AICl₃ treated rats.

that the chronic exposure to AICl₃ accelerated Aβ generation and diminished its degradation through enhancing the expression of APP, Aβ₁₋₄₂, β and γ secretases (2, 3, 39, 40). Exley, (41) reported that AI increases the Aβ burden in experimental animals through a direct impact on Aβ anabolism or direct or indirect influence on Aβ catabolism. In the present study, AA attenuated the AI induced Aβ toxicity by lowering the expressions of APP, Aβ₁₋₄₂, β and γ-secretases. AA inhibited the Aβ-induced cell death under *in vitro* conditions, through its anti-oxidative and anti-apoptotic actions (42). Jew *et al.*, (19) indicated that various derivatives of AA exhibited protective activity at different levels against Aβ-induced neurotoxicity *in vitro*. AA significantly down-regulated the expression of β-secretase and up-regulated the expression of α-secretase in primary

rat cortical neurons (43), which is corroborated with our present results.

Neuroinflammation is considered as a key feature in the pathology of AD and current target for therapeutic interventions. In AD, microglia, astrocytes and few neurons having significant functions in the homeostasis and function of the brain are the major players involved in the inflammatory process (44, 45). Reactive gliosis is a phenomenon during which astrocyte and microglia get activated in response to an array of toxins that contribute to the pathogenesis of neuroinflammation and neurodegeneration. GFAP is an astrocyte-specific intermediate filament protein essential for homeostasis of central nervous system and Ionized calcium-binding adapter molecule 1 (Iba-1) is a microglial specific protein, also known

as allograft inflammatory factor-1 (Alf1), are up-regulated in reactive gliosis following Al exposure (12). In our study, the enhanced expression of inflammatory markers in the hippocampus and cortex in AlCl_3 alone treated rats, demonstrated the reactive gliosis, whereas the attenuated expression of GFAP and Iba-1 during AA treatment suggested its anti-inflammatory role.

Previous studies indicated that the administration of various Al salt complexes can aggravate glial and astrocyte and further endorse an inflammatory cascade in the brain (12, 40, 46). In the present study, AlCl_3 administration enhanced the expressions of pro-inflammatory cytokines such as IL-1 β (key regulator of inflammation during host defence response), IL-4 (enhanced during the sustained IL-1 β neuroinflammation), IL-2 (numerous effects on hippocampal neurons, where its receptors are enriched, thus improving cognitive performances), IL-6 (mediator of the inflammatory and immune responses), TNF- α (trigger for other cytokines) (46, 47), whereas AA treatment attenuated the expressions of above said indices. Li *et al.*, (48) indicated that the treatment of AA attenuated lipopolysaccharide-induced TNF- α , IL-6 and IL-1 β production in acute lung injury in mice. Enhanced TNF- α expression activates the transcription factor NF- κ B. COX-2 expression in neurons can be induced by excitotoxic insults, transient global cerebral ischemia and oxidative stress as well as inflammatory mediators such as TNF- α (49). Proinflammatory cytokines exaggerated the oxidative/nitrosative stress by inducing iNOS gene expression through NF- κ B activation. In the CNS, NF- κ B transcription factors are key players in a number of physiological processes such as neurogenesis (50), neuritogenesis (51) and synaptic plasticity which related to learning and memory (52). Haung *et al.*, (53) revealed that AA decreased the expressions of iNOS, COX-2 and NF- κ B against λ -Carrageenin-induced edema. Diminished expressions of TNF- α , IL-1 β , COX-2 and iNOS were found in the cortex and hippocampus of rats treated with AA, which demonstrates that AA exerts anti-inflammatory effect through regulating the expression of NF- κ B.

To conclude, our observations suggested that AA treatment mitigated AlCl_3 induced AD associated pathologies including Al overloading, AChE hyperactivity, behavioural impairment, A β burden and inflammation, which may due to its multiple pharmacological action. It is suggested that the herbs having anti-inflammatory, antioxidant and anti-apoptotic activities could be useful in the treatment of AD (54, 55). Further studies are warranted to explore the link between AlCl_3 -mediated oxidative stress and associated apoptosis to establish the neuroprotective role of AA in AD.

6. ACKNOWLEDGMENTS

The authors declare that they have no conflict of interest concerning this article. This manuscript has been professionally edited by Red Fern Communication, NSW, Australia.

7. REFERENCES

1. T.P. Flaten: Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. *Brain Res Bull* 55, 187–196 (2001)
DOI: 10.1016/S0361-9230(01)00459-2
2. A. Justin Thenmozhi, T.R. William Raja, U. Janakiraman, T. Manivasagam: Neuroprotective effect of hesperidin on aluminium chloride induced Alzheimer's disease in wistar rats. *Neurochem Res* 40, 767–776 (2015)
DOI: 10.1007/s11064-015-1525-1
3. A. Justin Thenmozhi, M. Dhivyabharathi, T.R. William Raja, T. Manivasagam, M.M. Essa: Tannoid principles of *Embllica officinalis* renovate cognitive deficits and attenuate amyloid pathologies against aluminum chloride induced rat model of Alzheimer's disease. *Nutr Neurosci* 19, 269–278 (2016)
DOI: 10.1179/1476830515Y.0000000016
4. J.R. Walton: Cognitive deterioration and associated pathology induced by chronic low-level aluminum ingestion in a translational rat model provides an explanation of Alzheimer's disease, tests for susceptibility and avenues for treatment. *Int J Alzheimers Dis* 2012, 914–947 (2012)
DOI: 10.1155/2012/914947
5. S. Amjad, S. Umesalma: Protective effect of Centella asiatica against aluminium-induced neurotoxicity in cerebral cortex, striatum, hypothalamus and hippocampus of rat brain- histopathological, and biochemical approach. *J Mol Biomark Diagn* 212, 1–7 (2015)
DOI: 10.4172/2155-9929.1000212
6. A. Becaria, S.C. Bondy, A. Campbell: Aluminum and copper interact in the promotion of oxidative but not inflammatory events: implications for Alzheimer's disease. *J Alzheimers Dis* 5, 31–38 (2003)
DOI: 10.3233/JAD-2003-5105

7. O. Ghribi, D.A. DeWitt, M.S. Forbes, M.M. Herman, J. Savory: Co-involvement of mitochondria and endoplasmic reticulum in regulation of apoptosis: changes in cytochrome c, Bcl-2 and Bax in the hippocampus of aluminum-treated rabbits. *Brain Res* 903, 66–73 (2001)
DOI: 10.1016/S0006-8993(01)02406-4
8. S. Colak, F. Geyikoglu, O.N. Keles, H. Turkez, A. Topal, B. Unal: The neuroprotective role of boric acid on aluminum chloride-induced neurotoxicity. *Toxicol Ind Health* 27, 700–710 (2011)
DOI: 10.1177/0748233710395349
9. M.H. Veerendra Kumar, Y.K. Gupta: Effect of different extracts of *Centella asiatica* on cognition and markers of oxidative stress in rats. *J Ethnopharmacol* 79, 253–260 (2002)
DOI: 10.1016/S0378-8741(01)00394-4
10. N.E. Gray, J.A. Zweig, C. Kawamoto, J.F. Quinn, A. Soumyanath: Centella asiatica improves synaptic plasticity and activates antioxidant and mitochondrial pathways in hippocampal neurons from an Alzheimer's disease mouse model. *Planta Med* 82, S1–S381 (2016)
DOI: 10.1055/s-0036-1596958
11. A. Soumyanath, Y.P. Zhong, .E Henson, T. Wadsworth, J. Bishop, B.G. Gold, J.F. Quinn: Centella asiatica extract improves behavioral deficits in a mouse model of Alzheimer's disease: Investigation of a possible mechanism of action. *Int J Alzheimers Dis* 2012, 1–9 (2012)
DOI: 10.1155/2012/381974
12. A. Prakash, A. Kumar: Mitoprotective effect of Centella asiatica against aluminum induced neurotoxicity in rats: possible relevance to its anti-oxidant and anti-apoptosis mechanism. *Neurol Sci* 34, 1403–1409 (2013)
DOI: 10.1007/s10072-012-1252-1
13. C.J. Zheng, L.P. Qin: Chemical components of Centella asiatica and their bioactivities. *Zhong Xi Yi Jie He Xue Bao* 5, 348–351 (2007)
DOI: 10.3736/jcim20070324
14. R.G. Krishnamurthy, M.C. D. Senut, Zemke, J.Y. Min, M.B. Frenkel, E.J. Greenberg, S.W. Yu, N. Ahn, J. Goudreau, M. Kassab, K.S. Panickar, A. Majid: Asiatic acid, a pentacyclic triterpene from Centella asiatica, is neuroprotective in a mouse model of focal cerebral Ischemia. *J Neurosci Res* 87, 2541–2550 (2009)
DOI: 10.1002/jnr.22071
15. M.K. Lee, S.R. Kim, S.H. Sung, D.Y. Lim, H. Kim, H. Choi, H.K. Park, S. Je, Y.C. Ki: Asiatic acid derivatives protect cultured cortical neurons from glutamate-induced excitotoxicity. *Res Commun Mol Pathol Pharmacol* 108, 75–86 (2000)
16. J. Nataraj, T. Manivasagam, A. Justin Thenmozhi, M.M. Essa: Neuroprotective effect of asiatic acid on rotenone-induced mitochondrial dysfunction and oxidative stress-mediated apoptosis in differentiated SH-SY5Y cells. *Nutr Neurosci* 8, 1–9 (2016)
DOI: 10.1080/1028415X.2015.1135559
17. J. Nataraj, T. Manivasagam, A. Justin Thenmozhi, M.M. Essa: Neurotrophic effect of asiatic acid, a triterpene of centella asiatica against chronic 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine hydrochloride/probenecid mouse model of Parkinson's disease: The role of MAPK, PI3K-Akt-GSK3 β and mTOR signalling pathways. *Neurochem Res* 42, 1354–1365 (2017)
DOI: 10.1007/s11064-017-2183-2
18. M.F. Xu, Y.Y. Xiong, J.K. Liu, J.J. Qian, L. Zhu, J. Gao: Asiatic acid, a pentacyclic triterpene in Centella asiatica, attenuates glutamate-induced cognitive deficits in mice and apoptosis in SH-SY5Y cells. *Acta Pharmacol Sin* 33, 578–587 (2012)
DOI: 10.1038/aps.2012.3
19. S.S. Jew, Yoo, C.H. D.Y. Lim, H. Kim, I. Mook-Jung, M.W. Jung, H. Choi, Y.H. Jung, H. Kim, H.G. Park: Structure-activity relationship study of asiatic acid derivatives against beta amyloid (A β)-induced neurotoxicity. *Bioorg Med Chem Lett* 10, 119–121 (2000)
DOI: 10.1016/S0960-894X(99)00658-7
20. A. Justin Thenmozhi, T.R. William Raja, T. Manivasagam, U. Janakiraman, M.M. Essa: Hesperidin ameliorates cognitive dysfunction, oxidative stress and apoptosis against aluminium chloride induced rat model of Alzheimer's disease. *Nutr. Neurosci* 16, 1–9 (2016)
DOI: 10.1080/1028415X.2016.1144846
21. A. Justin Thenmozhi, M. Dhivyabharathi M, T. Manivasagam, M.M. Essa: Tannoid principles

- of *Embllica officinalis* attenuated aluminum chloride induced apoptosis by suppressing oxidative stress and tau pathology via Akt/GSK-3 β signaling pathway. *J Ethnopharmacol* 194, 20–29 (2016c)
DOI: 10.1016/j.jep.2016.08.047
22. R. Morris: Developments of a water-maze procedure for studying spatial learning in the rat. *J Neurosci Meth* 11, 47–60 (1984)
DOI: 10.1016/0165-0270(84)90007-4
23. A. Prema, A. Justin Thenmozhi, T. Manivasagam, M.M. Essa: M.D. Akbar, M. Akbar, Fenugreek seed powder nullified aluminium chloride induced memory loss, biochemical changes, A β burden and apoptosis via regulating Akt/GSK3 β signaling pathway. *PLoS One* 11, 1–19 (2016)
DOI: 10.1371/journal.pone.0165955
24. P. Sethi, A. Jyoti, R. Singh, E. Hussain, D. Sharma: Aluminium induced electrophysiological, biochemical and cognitive modifications in the hippocampus of aging rats. *Neurotoxicology* 29, 1069–1079 (2008)
DOI: 10.1016/j.neuro.2008.08.005
25. G.L. Ellman, K.D. Courtney, V. Andres, R.M. Featherstone: A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 7, 88–90 (1961)
DOI: 10.1016/0006-2952(61)90145-9
26. O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall: Protein measurement with the Folin phenol's reagent. *J Biol Chem* 193, 265–275 (1951)
27. U. Janakiraman, T. Manivasagam, A. Justin Thenmozhi, M.M. Essa, R. Barathidasan, C. Saravana Babu, G.J. Guillemain, M.A. Khan: Influences of chronic mild stress exposure on motor, non-motor impairments and neurochemical variables in specific brain areas of MPTP/probenecid induced neurotoxicity in mice. *PLoS One* 11, 1–19 (2016)
DOI: 10.1371/journal.pone.0146671
28. J.P. Day, J. Barker, L.J. Evans, J. Perks, P.J. Seabright, P. Ackrill, J.S. Lilley, P.V. Drumm, G.W. Newton: Aluminium absorption studied by ²⁶Al tracer. *Lancet* 337, 13–45 (1991)
DOI: 10.1016/0140-6736(91)93016-3
29. S. Oshiro, M. Kawahara, S. Mika, K. Muramoto, K. Kobayashi, R. Ishige, K. Nozawa, M. Hori, C. Yung, S. Kitajima, Y. Kuroda: Aluminum taken up by transferrin-independent iron uptake affects the iron metabolism in rat cortical cells. *J Biochem* 123, 42–46 (1998)
DOI: 10.1093/oxfordjournals.jbchem.a021914
30. R.A. Yokel, S.S. Rhineheimer, P. Sharma, D. Elmore, P.J. McNamara: Entry, half-life, and desferrioxamine accelerated clearance of brain aluminum after a single Al exposure. *Toxicol Sci* 64, 77–82 (2001)
DOI: 10.1093/toxsci/64.1.77
31. R.J. Mohd Salim, M.I. Adenan, A. Amid, M.H. Jauri, A.S. Sued: Statistical analysis of metal chelating activity of *Centella asiatica* and *Erythroxylumcuneatum* using response surface methodology. *Biotechnol Res Int* 2013, 1–5 (2013)
DOI: 10.1155/2013/137851
32. Z. Rakonczay, Z. Horvath, A. Juhasz, J. Kalman: Peripheral cholinergic disturbances in Alzheimer's disease. *Chem Biol Interact* 157, 233–238 (2005)
DOI: 10.1016/j.cbi.2005.10.034
33. P. Zatta, P. Zambenedetti, V. Bruna, B. Filippi: Activation of acetylcholinesterase by aluminium (III): the relevance of the metal species, *Neuroreport*. 5, 1777–1780 (1994)
DOI: 10.1097/00001756-199409080-00023
34. M.N. Nasir, J. Abdullah, M. Habsah, R.I. Ghani, G. Rammes: Inhibitory effect of asiatic acid on acetylcholinesterase, excitatory post synaptic potential and locomotor activity. *Phytomedicine* 19, 311–316 (2012)
DOI: 10.1016/j.phymed.2011.10.004
35. T. Baydar, A. Papp, A. Aydin, L. Nagymajtenyi, H. Schulz, A. Isimer, G. Sahin: Accumulation of aluminum in rat brain: Does it lead to behavioral and electrophysiological changes? *Biol Trace Elem Res* 92, 231–244 (2003)
DOI: 10.1385/BTER:92:3:231
36. M.J. West: Regionally specific loss of neurons in the aging human hippocampus. *Neurobiol. Aging* 14, 287–293 (1993)
DOI: 10.1016/0197-4580(93)90113-P
37. M.N. Nasir, M. Habsah, M.K.R. Adzim, A.H. Norhayati, D.V. Muralidhara, A.L. Zubaidi: Acute effects of triterpene compounds on locomotor performance and Morris water

- maze tasks in Sprague-Dawley rats. *Biomed Res* 26, 304–310 (2015)
38. K. Vekrellis, Z. Ye, W.Q. Qiu, D. Walsh, D. Hartley, V. Chesneau, M.R. Rosner, D.J. Selkoe: Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. *J. Neurosci.* 20, 1657–1665 (2000)
39. D.B. Mathiyazahan, A. Justin Thenmozhi, T. Manivasagam: Protective effect of black tea extract against aluminium chloride-induced Alzheimer's disease in rats: a behavioural, biochemical and molecular approach. *J Funct Foods* 16, 423–435 (2015)
DOI: 10.1016/j.jff.2015.05.001
40. A. Prema, A. Justin Thenmozhi, T. Manivasagam, M. Mohamed Essa, G.J. Guillemin: Fenugreek seed powder attenuated aluminum chloride-induced tau pathology, oxidative stress, and inflammation in a rat model of Alzheimer's Disease. *J Alzheimers Dis* 1–12 (2017)
DOI: 10.3233/JAD-161103
41. C. Exley: The aluminium-amyloid cascade hypothesis and Alzheimer's disease. *Subcell Biochem* 38, 225–234(2005)
DOI: 10.1007/0-387-23226-5_11
42. I. Jung, J. Shin, S.H. Yun, K. Huh, J.Y. Koh, H.K. Park, S. Jew, M.W. Jung: Protective effects of asiaticoside derivatives against Beta-amyloid neurotoxicity. *J Neurosci Res* 58, 417–425 (1999)
DOI:10.1002/(SICI)1097-4547(19991101)58:3<417::AID-JNR7>3.3.CO;2-
43. S.P. Patil, S. Maki, S.A. Khedkar, A.C. Rigby, C. Chan: Withanolide A and asiatic acid modulate multiple targets associated with amyloid-beta precursor protein processing and amyloid-beta protein clearance. *J Nat Prod* 73, 1196–1202 (2010)
DOI: 10.1021/np900633j
44. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Baue, , G.M. Cole: Inflammation and Alzheimer's disease. *Neuro. biol. Aging* 21, 383–421(2000a)
DOI: 10.1016/S0197-4580(00)00124-X
45. H. Akiyama, T. Arai, H. Kondo, E. Tanno, C. Haga, K. Ikeda: Cell mediators of inflammation in the Alzheimer disease brain. *Alzheimer Dis Assoc Disord* 14, S47–S53 (2000)
DOI: 10.1097/00002093-200000001-00008
46. A. Jangra, P. Kasbe, S.N. Pandey, S. Dwivedi, S.S. Gurjar, M. Kwatra, M. Mishra, A.K. Venu, K. Sulakhiya, R. Gogoi, N. Sarma, B.K. Bezbaruah, M. Lahkar: Hesperidin and silibinin ameliorate aluminum-induced neurotoxicity: modulation of antioxidants and inflammatory cytokines level in mice hippocampus. *BiolTrace. Elem Res* 168, 462–471(2015)
DOI: 10.1007/s12011-015-0375-7
47. A. Campbell, A. Becaria, D.K. Lahiri, K. Sharman, S.C. Bondy: Chronic exposure to aluminium in drinking water increases inflammatory parameters selectively in the brain. *J Neurosci Res* 75, 565–572(2004)
DOI: 10.1002/jnr.10877
48. Z. Li, X. Xiao , M. Yang: Asiatic acid inhibits lipopolysaccharide-induced acute lung injury in mice. *Inflammation* 39, 1642–1648 (2016)
DOI: 10.1007/s10753-016-0398-z
49. H. Wang, M. Ye, L. Yu, J. Wang: Hippocampal neuronal cyclooxygenase-2 downstream signaling imbalance in a rat model of chronic aluminium gluconate administration. *Behav Brain Funct* 11, 1–12 (2015)
DOI: 10.1186/s12993-015-0054-z
50. J.W. Koo, S.J. Russo, D. Ferguson, E.J. Nestler: Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. *Proc Natl Acad Sci U.S.A.* 107, 2669–2674 (2010)
DOI: 10.1073/pnas.0910658107
51. A. Rolls, R. Shechter, A. London, Y. Ziv: Toll-like receptors modulate adult hippocampal neurogenesis. *Nat Cell Biol* 9, 1081–1088 (2007)
DOI: 10.1038/ncb1629
52. H.J. Ahn, C.M. Hernandez, J.M. Levenson, F.D. Lubin: c-Rel, an NF-kappaB family transcription factor, is required for hippocampal long-term synaptic plasticity and memory formation. *Learn Mem* 15, 539–549(2008)
DOI: 10.1101/lm.866408
53. S.S. Huang, C.S. Chiu, H.J. Chen, W.C. Hou: Antinociceptive activities and the

mechanisms of anti-inflammation of asiatic acid in mice. *Evid Based Complement Alternat Med* 2011, 1–10 (2011)
DOI: 10.1155/2011/895857

54. A.K. Singhal, V. Naithani, O.P. Bangar: Medicinal plants with a potential to treat Alzheimer and associated symptoms. *Int J Nutr Pharmacol Neurol Dis* 2, 84–91(2012)
DOI: 10.4103/2231-0738.95927
55. P.R. Bhandari: Dietary approach for cognitive and behavioral problems in dementia. *Int J Nutr Pharmacol Neurol Dis* 3, 398–400 (2013)
DOI: 10.4103/2231-0738.119861

Key Words: Alzheimer's disease, Asiatic Acid, Memory Deficits, Amyloid Pathology, Inflammation

Send correspondence to: Arokiasamy Justin Thenmozhi, Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Tamil Nadu 608002, India, Tel: 91 04144 239458, E-mail: justinthenmozhi@rediffmail.com